Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on the stock and has a $6.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee’s rating is based on several promising developments within Opus Genetics. The clearance of the IND for OPGx-BEST1, aimed at treating retinal diseases caused by BEST1 mutations, is a significant milestone, with human trials expected to begin in the latter half of 2025. This development, coupled with positive preclinical data, suggests a potential for substantial vision improvements, making it a key value driver for the company.
Additionally, the progress in the OPGx-LCA5 program, which has shown early signs of visual function improvement in pediatric trials, is encouraging. The anticipated regulatory discussions with the FDA in late 2025 could expedite the path to market, especially given the focus on pediatric blindness as a priority for faster drug approvals. Furthermore, the company’s solid cash position and potential additional funding from warrant exercises provide a stable financial foundation, supporting the Buy rating.
In another report released on August 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.